These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 37199326)

  • 1. Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.
    Hughes RT; Gebeyehu RR; Kalada JM; Lycan TW; Frizzell BA; Kinney RD; D'Agostino RB; Bunch PM; Triozzi P; Zhang W; Furdui CM; Porosnicu M
    Future Oncol; 2023 Jul; 19(22):1523-1534. PubMed ID: 37199326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation Therapy Oncology Group 8502 "QUAD shot" regimen using volumetric modulated arc therapy for incurable head and neck cancer.
    Toya R; Fukugawa Y; Saito T; Matsuyama T; Yoshida R; Murakami D; Orita Y; Nakayama H; Oya N
    Oral Oncol; 2024 Apr; 151():106752. PubMed ID: 38518555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclical hypofractionated radiotherapy also known as "QUAD Shot" alone using intensity-modulated radiotherapy for squamous cell carcinoma of the parotid gland in an 85-year-old patient with multiple comorbidities.
    Kil WJ; Camphausen K
    Head Neck; 2017 Apr; 39(4):E55-E60. PubMed ID: 28170130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for head and neck cancer: Fundamentals and therapeutic development.
    Okano S
    Auris Nasus Larynx; 2024 Aug; 51(4):684-695. PubMed ID: 38729034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated Palliative Radiotherapy with Concurrent Radiosensitizing Chemotherapy for Advanced Head and Neck Cancer Using the "QUAD-SHOT Regimen".
    Gamez ME; Agarwal M; Hu KS; Lukens JN; Harrison LB
    Anticancer Res; 2017 Feb; 37(2):685-691. PubMed ID: 28179317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclical hypofractionated radiotherapy technique for palliative treatment of locally advanced head and neck cancer: institutional experience and review of palliative regimens.
    Finnegan TS; Bhatt NH; Shaughnessy JN; Perez C; Redman R; Silverman C; Bumpous J; Potts K; Dunlap NE
    J Community Support Oncol; 2016 Jan; 14(1):29-36. PubMed ID: 26870840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
    Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
    Front Immunol; 2021; 12():652054. PubMed ID: 34305889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated palliative volumetric modulated arc radiotherapy with the Radiation Oncology Study Group 8502 "QUAD shot" regimen for incurable head and neck cancer.
    Toya R; Saito T; Yamaguchi K; Matsuyama T; Watakabe T; Matsumoto T; Yoshida R; Hirosue A; Murakami D; Orita Y; Nakayama H; Oya N
    Radiat Oncol; 2020 May; 15(1):123. PubMed ID: 32460865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of Near-infrared Photoimmunotherapy Combined With Immune Checkpoint Inhibitor Therapy in Unresectable Head and Neck Cancer.
    Hirakawa H; Ikegami T; Kinjyo H; Hayashi Y; Agena S; Higa T; Kondo S; Toyama M; Maeda H; Suzuki M
    Anticancer Res; 2024 Sep; 44(9):3907-3912. PubMed ID: 39197908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot.
    Ma J; Lok BH; Zong J; Gutiontov SI; Cai X; Bell AC; Shcherba M; Xiao H; Sherman EJ; Tsai CJ; Riaz N; McBride SM; Cahlon O; Lee NY
    Int J Part Ther; 2018; 4(4):10-19. PubMed ID: 30246055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional Fractionation versus Quad Shot in Advanced Head-and-Neck Cancers: A Randomized Controlled Trial.
    Choudhary A; Gupta A
    Indian J Palliat Care; 2019; 25(4):527-534. PubMed ID: 31673207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current immuno-oncology in head and neck cancer].
    Burian M; Neuchrist C
    Wien Med Wochenschr; 2022 Feb; 172(1-2):31-34. PubMed ID: 34185219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
    Daste A; Larroquette M; Gibson N; Lasserre M; Domblides C
    Immunotherapy; 2024 Feb; 16(3):187-197. PubMed ID: 38126161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for squamous cell carcinoma of the head and neck.
    Yokota T; Homma A; Kiyota N; Tahara M; Hanai N; Asakage T; Matsuura K; Ogawa T; Saito Y; Sano D; Kodaira T; Motegi A; Yasuda K; Takahashi S; Tanaka K; Onoe T; Okano S; Imamura Y; Ariizumi Y; Hayashi R;
    Jpn J Clin Oncol; 2020 Sep; 50(10):1089-1096. PubMed ID: 32776100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.